ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- • First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries
• START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of the international Phase III START2 study, which is designed to assess the efficacy and safety of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Help employers find you! Check out all the jobs and post your resume.
